OrganiGram Holdings Net Income From Continuing Ops Over Time
| OGI Stock | USD 1.44 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out OrganiGram Holdings Performance and OrganiGram Holdings Correlation. OrganiGram | Build AI portfolio with OrganiGram Stock |
Is there potential for Pharmaceuticals market expansion? Will OrganiGram introduce new products? Factors like these will boost the valuation of OrganiGram Holdings. Anticipated expansion of OrganiGram directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.11 | Revenue Per Share | Quarterly Revenue Growth 0.487 | Return On Assets | Return On Equity |
Investors evaluate OrganiGram Holdings using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating OrganiGram Holdings' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause OrganiGram Holdings' market price to deviate significantly from intrinsic value.
It's important to distinguish between OrganiGram Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding OrganiGram Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, OrganiGram Holdings' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare OrganiGram Holdings and related stocks such as Journey Medical Corp, InfuSystems Holdings, and Aurora Cannabis Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DERM | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 5.3 M | (44 M) | (29.6 M) | (12.4 M) | (14.7 M) | (13.2 M) | (13.9 M) |
| INFU | (45.4 M) | (45.4 M) | (1.5 M) | 1.7 M | 3.4 M | 2.8 M | (222 K) | (20.7 M) | (1.1 M) | 1.4 M | 17.3 M | 1.4 M | 18 K | 907 K | 2.3 M | 2.7 M | 2.8 M |
| ACB | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (5.7 M) | (13 M) | 69.2 M | (297.9 M) | (3.3 B) | (693.5 M) | (1.7 B) | (1.8 B) | (59 M) | 15.8 M | 14.2 M | 14.9 M |
| HSDT | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (9.8 M) | (6.9 M) | (12 M) | (28 M) | (28.6 M) | (9.8 M) | (14.1 M) | (18.1 M) | (14.1 M) | (12.7 M) | (11.7 M) | (10.6 M) | (11.1 M) |
| RNAC | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (25.2 M) | (36.2 M) | (65.3 M) | (65.3 M) | (55.4 M) | (68.9 M) | (25.7 M) | 35.4 M | (219.7 M) | (77.4 M) | (69.7 M) | (73.2 M) |
| OBIO | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (23 M) | (33.6 M) | (49.1 M) | (61 M) | (54.9 M) | (57.7 M) |
| IVA | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (17.2 M) | (33.6 M) | (30.2 M) | (33.6 M) | (49.6 M) | (54.3 M) | (110.4 M) | (184.2 M) | (165.8 M) | (157.5 M) |
| SXTC | 141.5 K | 141.5 K | 141.5 K | 141.5 K | 141.5 K | 141.5 K | 1.2 M | 1.2 M | 1.5 M | (10.3 M) | (2.7 M) | (5.7 M) | (5.9 M) | (3.1 M) | (3.3 M) | (3 M) | (3.1 M) |
| LFCR | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | (38.2 M) | (32.7 M) | (46.3 M) | (69 M) | 9.3 M | (38.7 M) | (34.8 M) | (36.6 M) |
| ELMD | 186.6 K | 186.6 K | (1.3 M) | (1.3 M) | 1.1 M | 2.2 M | 2.2 M | 1.9 M | 2 M | 4.2 M | 2.4 M | 2.3 M | 3.2 M | 5.2 M | 7.5 M | 8.7 M | 9.1 M |
OrganiGram Holdings and related stocks such as Journey Medical Corp, InfuSystems Holdings, and Aurora Cannabis Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| OrganiGram Holdings | OGI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 145 King Street |
| Exchange | NASDAQ Exchange |
USD 1.44
Check out OrganiGram Holdings Performance and OrganiGram Holdings Correlation. For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
OrganiGram Holdings technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.